Log in
Enquire now
‌

US Patent 11332537 Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Celldex Therapeutics
Celldex Therapeutics
Current Assignee
Celldex Therapeutics
Celldex Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11332537
Date of Patent
May 17, 2022
Patent Application Number
17405861
Date Filed
August 18, 2021
Patent Citations
‌
US Patent 10633444 Agonistic antibodies that bind CD40
‌
US Patent 10556957 Anti-CD27 antibodies
‌
US Patent 11180566 Antibodies that bind human CD27 and uses thereof
Patent Citations Received
‌
US Patent 11459393 Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
Patent Primary Examiner
‌
Lynn A Bristol
CPC Code
‌
C07K 16/2878
‌
C07K 2317/565
‌
C07K 2317/622

Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11332537 Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.